TAM
IRD

Tucker Asset Management’s Opus Genetics IRD Stock Holding History

Tucker Asset Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-29,106
Closed -$126K – 1581
2023
Q2 		$126K Buy
+29,106
New +$138K 0.04% 145

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Tucker Asset Management's IRD Position: Q3 2023 in Review

Tucker Asset Management sold out of Opus Genetics (IRD) in Q3 2023, closing a stake of 29,106 shares — an estimated $126K sold.

Tucker Asset Management first reported a position in IRD in Q2 2023 and held it in 1 quarter. The position peaked at $126K in Q2 2023. 49 funds tracked by Wall St. Rank hold IRD as of Q3 2023.

  • Tucker Asset Management reported no remaining Opus Genetics position as of Q3 2023 after selling out during the quarter.
  • Tucker Asset Management sold 29,106 Opus Genetics shares in Q3 2023, an estimated $126K.
  • Tucker Asset Management first reported a position in Opus Genetics in Q2 2023 and held it in 1 quarter.
  • Tucker Asset Management's Opus Genetics position peaked at $126K in Q2 2023.
  • 49 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2023.

Based on Tucker Asset Management's 13F filing for Q3 2023, filed 4 Dec 2023.